Janet Jill Hopkins Sells 2,534 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of Aura Biosciences stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total value of $19,638.50. Following the completion of the transaction, the insider now owns 269,794 shares in the company, valued at approximately $2,090,903.50. This represents a 0.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Aura Biosciences Price Performance

Aura Biosciences stock opened at $7.65 on Thursday. The business has a 50 day moving average of $8.02 and a 200-day moving average of $8.74. The company has a market capitalization of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29. Aura Biosciences, Inc. has a 1 year low of $6.63 and a 1 year high of $12.38.

Analyst Ratings Changes

Several brokerages recently issued reports on AURA. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $23.00.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Long Focus Capital Management LLC lifted its holdings in shares of Aura Biosciences by 123.9% during the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock worth $20,861,000 after purchasing an additional 1,404,228 shares during the period. Levin Capital Strategies L.P. raised its position in Aura Biosciences by 169.1% during the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after purchasing an additional 783,984 shares during the last quarter. B Group Inc. bought a new position in Aura Biosciences during the 4th quarter worth $3,885,000. Franklin Resources Inc. lifted its holdings in Aura Biosciences by 14.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after buying an additional 215,597 shares during the period. Finally, Ensign Peak Advisors Inc grew its position in shares of Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after buying an additional 118,000 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.